中国蒽环类药物治疗乳腺癌专家共识

2018-03-20 中国抗癌协会肿瘤临床化疗专业委员会 中国肿瘤临床.2018,45(3):120-125.

20 世纪80 年代,蒽环类药物(anthracyclines)以其卓越的疗效成为乳腺癌术后辅助化疗的里程碑。在新型药物涌现、多种治疗模式并存的循证医学时代,即使重新审视,仍可发现蒽环类药物不仅在乳腺癌术后辅助化疗中占有极其重要的地位,而且在新辅助化疗、晚期乳腺癌患者治疗中也据有一席之地。为了进一步明确蒽环类药物在乳腺癌中的治疗作用,准确评估蒽环类药物的临床疗效及不良反应,减少治疗的盲目性并增强规

中文标题:

中国蒽环类药物治疗乳腺癌专家共识

发布日期:

2018-03-20

简要介绍:

20 世纪80 年代,蒽环类药物(anthracyclines)以其卓越的疗效成为乳腺癌术后辅助化疗的里程碑。在新型药物涌现、多种治疗模式并存的循证医学时代,即使重新审视,仍可发现蒽环类药物不仅在乳腺癌术后辅助化疗中占有极其重要的地位,而且在新辅助化疗、晚期乳腺癌患者治疗中也据有一席之地。为了进一步明确蒽环类药物在乳腺癌中的治疗作用,准确评估蒽环类药物的临床疗效及不良反应,减少治疗的盲目性并增强规范性,中国抗癌协会肿瘤临床化疗专业委员会组织乳腺癌专家,在近几年新的国内外研究成果的基础上,制定《中国蒽环类药物治疗乳腺癌专家共识》并作为《中国蒽环类药物治疗恶性肿瘤专家共识》系列的重要组成部分发表。

 

拓展指南:乳腺癌相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=中国蒽环类药物治疗乳腺癌专家共识)] GetToolGuiderByIdResponse(projectId=1, id=9e34e1c0015ea7be, title=中国蒽环类药物治疗乳腺癌专家共识, enTitle=, guiderFrom=中国肿瘤临床.2018,45(3):120-125., authorId=null, author=, summary=20 世纪80 年代,蒽环类药物(anthracyclines)以其卓越的疗效成为乳腺癌术后辅助化疗的里程碑。在新型药物涌现、多种治疗模式并存的循证医学时代,即使重新审视,仍可发现蒽环类药物不仅在乳腺癌术后辅助化疗中占有极其重要的地位,而且在新辅助化疗、晚期乳腺癌患者治疗中也据有一席之地。为了进一步明确蒽环类药物在乳腺癌中的治疗作用,准确评估蒽环类药物的临床疗效及不良反应,减少治疗的盲目性并增强规, cover=, journalId=null, articlesId=null, associationId=897, associationName=中国抗癌协会肿瘤临床化疗专业委员会, associationIntro=null, copyright=0, guiderPublishedTime=Tue Mar 20 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>20 世纪80 年代,蒽环类药物(anthracyclines)以其卓越的疗效成为乳腺癌术后辅助化疗的里程碑。在新型药物涌现、多种治疗模式并存的循证医学时代,即使重新审视,仍可发现蒽环类药物不仅在乳腺癌术后辅助化疗中占有极其重要的地位,而且在新辅助化疗、晚期乳腺癌患者治疗中也据有一席之地。为了进一步明确蒽环类药物在乳腺癌中的治疗作用,准确评估蒽环类药物的临床疗效及不良反应,减少治疗的盲目性并增强规范性,中国抗癌协会肿瘤临床化疗专业委员会组织乳腺癌专家,在近几年新的国内外研究成果的基础上,制定《中国蒽环类药物治疗乳腺癌专家共识》并作为《中国蒽环类药物治疗恶性肿瘤专家共识》系列的重要组成部分发表。 </P> <P> </P>拓展指南:<strong>与<font color=red>乳腺癌</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=b25b61c0015ea1c3" title="NCCN临床实践指南:乳腺癌(2018.V1)" target=_blank>NCCN临床实践指南:乳腺癌(2018.V1)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=6895d1c00155e814" title="NCCN临床实践指南:乳腺癌(2017.V4)" target=_blank>NCCN临床实践指南:乳腺癌(2017.V4)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=e66fa1c0015520af" title="2018 AHA科学声明:心血管疾病和乳腺癌" target=_blank>2018 AHA科学声明:心血管疾病和乳腺癌</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=065391c001551898" title="NCCN临床实践指南:降低乳腺癌风险(2018.V1)" target=_blank>NCCN临床实践指南:降低乳腺癌风险(2018.V1)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=571531c0015a2956" title="中国晚期乳腺癌维持治疗专家共识" target=_blank>中国晚期乳腺癌维持治疗专家共识</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E4%B9%B3%E8%85%BA%E7%99%8C" target=_blank>有关乳腺癌更多指南</a></ul>, tagList=[TagDto(tagId=27019, tagName=蒽环类药物), TagDto(tagId=285, tagName=乳腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7418, appHits=375, showAppHits=0, pcHits=5343, showPcHits=2425, likes=207, shares=9, comments=4, approvalStatus=1, publishedTime=Sun Apr 01 21:25:30 CST 2018, publishedTimeString=2018-03-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Apr 01 21:25:30 CST 2018, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 17:21:26 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=中国蒽环类药物治疗乳腺癌专家共识)])
中国蒽环类药物治疗乳腺癌专家共识
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1201498, encodeId=1e191201498bd, content=啧啧啧~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Thu Mar 10 19:39:38 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965409, encodeId=98a0965409ee, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332f5485634, createdName=ms4000000208539472, createdTime=Fri May 14 02:51:56 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322460, encodeId=bfcc322460f2, content=认真学习.希望每天多一些新进展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jun 08 10:12:16 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301829, encodeId=e1b43018292e, content=不错的文章值得推荐, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Apr 01 22:30:21 CST 2018, time=2018-04-01, status=1, ipAttribution=)]
    2022-03-10 Ms🧐🧐🧐🧐🧐🧐

    啧啧啧~

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1201498, encodeId=1e191201498bd, content=啧啧啧~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Thu Mar 10 19:39:38 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965409, encodeId=98a0965409ee, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332f5485634, createdName=ms4000000208539472, createdTime=Fri May 14 02:51:56 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322460, encodeId=bfcc322460f2, content=认真学习.希望每天多一些新进展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jun 08 10:12:16 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301829, encodeId=e1b43018292e, content=不错的文章值得推荐, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Apr 01 22:30:21 CST 2018, time=2018-04-01, status=1, ipAttribution=)]
    2021-05-14 ms4000000208539472

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1201498, encodeId=1e191201498bd, content=啧啧啧~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Thu Mar 10 19:39:38 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965409, encodeId=98a0965409ee, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332f5485634, createdName=ms4000000208539472, createdTime=Fri May 14 02:51:56 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322460, encodeId=bfcc322460f2, content=认真学习.希望每天多一些新进展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jun 08 10:12:16 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301829, encodeId=e1b43018292e, content=不错的文章值得推荐, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Apr 01 22:30:21 CST 2018, time=2018-04-01, status=1, ipAttribution=)]
    2018-06-08 phoebeyan520

    认真学习.希望每天多一些新进展

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1201498, encodeId=1e191201498bd, content=啧啧啧~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Thu Mar 10 19:39:38 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965409, encodeId=98a0965409ee, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332f5485634, createdName=ms4000000208539472, createdTime=Fri May 14 02:51:56 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322460, encodeId=bfcc322460f2, content=认真学习.希望每天多一些新进展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jun 08 10:12:16 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301829, encodeId=e1b43018292e, content=不错的文章值得推荐, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Apr 01 22:30:21 CST 2018, time=2018-04-01, status=1, ipAttribution=)]
    2018-04-01 131****2916

    不错的文章值得推荐

    0